Omalizumab for Severe Allergic Asthma: 7 Years and Open Questions

    loading  Checking for direct PDF access through Ovid

Abstract

Anti-IgE treatment for severe allergic asthma has been available for more than seven years now. This treatment has clear clinical benefits and a good safety record. However, important questions concerning long-term dosing and treatment duration remain unanswered. This paper discusses the available information concerning the long-term use of omalizumab.

Related Topics

    loading  Loading Related Articles